Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

New UCL cancer research centre launched in UK

A new centre is launched in London today (Wednesday), joining a select group of Cancer Research UK Centres across the UK.

14 Oct 2009

Celling Technologies announces positive outcome of Res-Q System in its initial applications

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q(TM) 60 BMC ("Res-Q") System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC.

14 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

NIH funds the University of California's consortium for immune disorder research

The University of California, San Francisco has been designated to lead a new consortium that will study a group of severe immune disorders known as primary immunodeficiencies and aims to improve treatment for these often life-threatening diseases. The Primary Immune Deficiency Treatment Consortium comprises 13 centers throughout the United States and has a $6.25 million funding commitment over five years from the National Institutes of Health.

13 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

The American Society of Hematology (ASH) is proud to announce the participants in the 2009 ASH Visitor Training Program, which builds hematologic capacity in developing countries. Through this program, hematologists and medical professionals from developing countries receive valuable clinical, laboratory, or technological training on a specific topic at a host institution under the mentorship of an ASH member anywhere in the world.

12 Oct 2009

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Two teams led by Massachusetts General Hospital (MGH) researchers, also members of the Harvard Stem Cell Institute (HSCI), are among 18 groups receiving National Heart Lung and Blood Institute (NHLBI) grants for the development of stem-cell based tools and treatments to understand and treat cardiovascular and blood disorders.

9 Oct 2009

CTRC-AACR San Antonio Breast Cancer Symposium to honor two leading breast cancer researchers

The CTRC-AACR San Antonio Breast Cancer Symposium will honor two leading breast cancer researchers when it holds its 32nd annual meeting Dec. 9-13, in San Antonio.

8 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

pDCs promote growth and survival of malignant myeloma cells

Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor - to switch from defending the body against disease to shielding the myeloma cells from harm - Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.

6 Oct 2009

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today awarded Dr. Mari Hashitate Dallas of St. Jude Children’s Research Hospital in Memphis, Tenn., the Millipore Guava® Flow Cytometry Award.

6 Oct 2009

Survival rates for multivisceral transplants increase with new treatment strategies

Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, said researchers at the Thomas E. Starzl Transplantation Institute in a study published in the October issue of Annals of Surgery.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

FOLOTYN available for commercial sale in the United States

Allos Therapeutics, Inc. today announced that FOLOTYN (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate.

6 Oct 2009

Bone Marrow News and Research

Further Reading

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Research scientists develop bioengineered treatment for targeting pancreatic cancer

SCID infants who receive early bone marrow transplants are likely to have fewer complications

New UCL cancer research centre launched in UK

Celling Technologies announces positive outcome of Res-Q System in its initial applications

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

NIH funds the University of California's consortium for immune disorder research

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

CTRC-AACR San Antonio Breast Cancer Symposium to honor two leading breast cancer researchers

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Scientists create new technology to improve detection of leukemia cells in bone marrow

pDCs promote growth and survival of malignant myeloma cells

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

Survival rates for multivisceral transplants increase with new treatment strategies

Schering-Plough receives FDA recommendation approval for PEGINTRON

FOLOTYN available for commercial sale in the United States

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News